hackint0sh/temp-data huggingface dataset:
protocolSection identificationModule nctId: NCT06337799, orgStudyIdInfo id: 202210411, briefTitle: Use of Allied-health Professionals to Improve Treatment of Disease, statusModule overallStatus: NOT_YET_RECRUITING, startDateStruct date: 2026-10, primaryCompletionDateStruct date: 2030-03, completionDateStruct date: 2030-03, studyFirstPostDateStruct date: 2024-03-29, lastUpdatePostDateStruct date: 2024-03-29, sponsorCollaboratorsModule leadSponsor name: University of Iowa, class: OTHER, descriptionModule briefSummary: The goal of this clinical trial is to learn if allied-health professionals can recruit and follow research participants, sustain engagement, and improve and diagnose treatment of diseases by facilitating transitions of care.Participants will:Take their blood pressure at home and return it to the research team; Follow up with a research pharmacist for 12 months; Return for a follow up visit after 12 months., conditionsModule conditions: Preeclampsia, designModule studyType: INTERVENTIONAL, phases: NA, designInfo allocation: NA, interventionModel: SINGLE_GROUP, primaryPurpose: PREVENTION, maskingInfo masking: NONE, enrollmentInfo count: 200, type: ESTIMATED, armsInterventionsModule interventions name: Research Pharmacist, outcomesModule primaryOutcomes measure: Number of Subjects at Risk for Hypertension, primaryOutcomes measure: Number of Subjects Exposed to a Screening Clinic, primaryOutcomes measure: Number of Subjects Screened at a Screening Clinic, primaryOutcomes measure: Number of Subjects Followed-Up by the Research Pharmacist, primaryOutcomes measure: Number of Subjects Diagnosed with Hypertension, primaryOutcomes measure: Number of Subjects Treated for Hypertension, if Diagnosed, eligibilityModule sex: FEMALE, minimumAge: 18 Years, maximumAge: 55 Years, stdAges: ADULT, contactsLocationsModule, hasResults: False
protocolSection identificationModule nctId: NCT06337773, orgStudyIdInfo id: B-BR-112-036, briefTitle: Developing the Precision Nursing Education Program to Young Colorectal Cancer Survivors, statusModule overallStatus: NOT_YET_RECRUITING, startDateStruct date: 2024-03-20, primaryCompletionDateStruct date: 2024-09-30, completionDateStruct date: 2026-12-25, studyFirstPostDateStruct date: 2024-03-29, lastUpdatePostDateStruct date: 2024-03-29, sponsorCollaboratorsModule leadSponsor name: Fooyin University, class: OTHER, descriptionModule briefSummary: This study is aimed to demonstrate the long-term effectiveness of 8-week precision nursing education program through the e-flipped classroom model for YCC survivors and provide a compliant strategy to improve quality of life and emotional status of these patients., conditionsModule conditions: Depression, designModule studyType: INTERVENTIONAL, phases: NA, designInfo allocation: RANDOMIZED, interventionModel: PARALLEL, primaryPurpose: SUPPORTIVE_CARE, maskingInfo masking: SINGLE, whoMasked: OUTCOMES_ASSESSOR, enrollmentInfo count: 110, type: ESTIMATED, armsInterventionsModule interventions name: 8-weeks's on-line precision nursing education program, outcomesModule primaryOutcomes measure: The depression symptoms on young colorectal cancer survivors, secondaryOutcomes measure: Dispositional mindfulness status on young colorectal cancer survivors, secondaryOutcomes measure: General quality of life on young colorectal cancer survivors, secondaryOutcomes measure: Colorectal specific quality of life on young colorectal cancer survivors, secondaryOutcomes measure: Cancer threat appraisal on young colorectal cancer survivors, eligibilityModule sex: ALL, minimumAge: 20 Years, maximumAge: 50 Years, stdAges: ADULT, contactsLocationsModule, hasResults: False
protocolSection identificationModule nctId: NCT06337760, orgStudyIdInfo id: IEO 1669, briefTitle: YOUNg Adults With Gastro-inteSTinal (GI) and nEuroendocrine canceRs., acronym: YOUNGSTER, statusModule overallStatus: RECRUITING, startDateStruct date: 2023-03-10, primaryCompletionDateStruct date: 2026-12-31, completionDateStruct date: 2027-06-30, studyFirstPostDateStruct date: 2024-03-29, lastUpdatePostDateStruct date: 2024-03-29, sponsorCollaboratorsModule leadSponsor name: European Institute of Oncology, class: OTHER, descriptionModule briefSummary: The objective of the study is to create a common and unique platform for the acquisition of biological samples and, subsequently, the possible identification of predictive and prognostic biomarkers for young adults with gastrointestinal and neuroendocrine cancers.The definition "adolescent and young adults (AYA)" covers a broad group of patients ranging from the upper limit of the paediatric competence to the youngest patients usually considered and treated as adults. However, a well-defined and universally accepted age range is still not established. Young adults with cancer have distinct epidemiological, biological, and clinical characteristics, as well as special medical and psychosocial needs that are often unmet. In consideration of their poor representation in clinical studies, as well as the rarer, albeit increasing, frequency at an epidemiological level, knowledge of the risk factors associated with cancers in young adults is very poor. It is therefore of fundamental importance to focus attention on this specific cohort of patients, in order to describe in ever more detail any specific biomolecular aspects, and make full use of the pharmacological resources currently available., conditionsModule conditions: Neuroendocrine Neoplasm, conditions: Adenocarcinoma, designModule studyType: OBSERVATIONAL, designInfo observationalModel: CASE_ONLY, timePerspective: OTHER, enrollmentInfo count: 90, type: ESTIMATED, armsInterventionsModule, outcomesModule primaryOutcomes measure: Numbers of partecipants with genetic alterations, secondaryOutcomes measure: Number of partecipants with survival outcomes, secondaryOutcomes measure: Number of partecipants toxicities, eligibilityModule sex: ALL, minimumAge: 18 Years, maximumAge: 39 Years, stdAges: ADULT, contactsLocationsModule locations facility: European Institute of Oncology, status: RECRUITING, city: Milan, country: Italy, contacts name: Lorenzo Gervaso, MD, role: CONTACT, contacts name: Chiara Alessandra Cella, MD, role: SUB_INVESTIGATOR, contacts name: Luca Mazzarella, MD, role: SUB_INVESTIGATOR, geoPoint lat: 45.46427, lon: 9.18951, hasResults: False
protocolSection identificationModule nctId: NCT06337747, orgStudyIdInfo id: 04-2023-PLLA, briefTitle: Comparing Injections With Poly-L-Lactic Acid in the Temporal Fossa vs. Extended Temporal Fossa + Hairline, statusModule overallStatus: RECRUITING, startDateStruct date: 2023-05-19, primaryCompletionDateStruct date: 2024-04-30, completionDateStruct date: 2024-06, studyFirstPostDateStruct date: 2024-03-29, lastUpdatePostDateStruct date: 2024-03-29, sponsorCollaboratorsModule leadSponsor name: Erevna Innovations Inc., class: OTHER, descriptionModule briefSummary: The use of poly-L-Lactic acid (PLLA) has demonstrated significant improvement in multiple facial and body regions. Its use in the temporal fossa is the ideal location to demonstrate its impact on neocollagenesis given its distinct anatomic boundaries. Furthermore, the fact that the lateral boundary of the temporal region can extend into the hairline allows for a graded effect to be measured. Therefore, this study aims to extend these findings by evaluating the efficacy and safety of two injection techniques for volumizing temporal hollows., conditionsModule conditions: Aging, designModule studyType: INTERVENTIONAL, phases: NA, designInfo allocation: RANDOMIZED, interventionModel: SINGLE_GROUP, interventionModelDescription: A prospective, randomized-controlled trial, primaryPurpose: TREATMENT, maskingInfo masking: NONE, enrollmentInfo count: 24, type: ESTIMATED, armsInterventionsModule interventions name: Traditional technique, interventions name: Experimental technique, outcomesModule primaryOutcomes measure: To access the efficacy of the tradition and experimental technique, secondaryOutcomes measure: To access the safety of the tradition and experimental technique, eligibilityModule sex: ALL, minimumAge: 18 Years, maximumAge: 75 Years, stdAges: ADULT, stdAges: OLDER_ADULT, contactsLocationsModule locations facility: Erevna Innovations Inc, status: RECRUITING, city: Montreal, state: Quebec, zip: H3R 3A1, country: Canada, contacts name: Andreas Nikolis, MD, role: CONTACT, phone: 514-488-0163, email: research@vicpark.com, geoPoint lat: 45.50884, lon: -73.58781, hasResults: False
protocolSection identificationModule nctId: NCT06337734, orgStudyIdInfo id: 2, briefTitle: An Artificial Intelligence-Assisted Digital Health Lifestyle Intervention for Adults With Hypertension, statusModule overallStatus: COMPLETED, startDateStruct date: 2021-11-01, primaryCompletionDateStruct date: 2023-08-01, completionDateStruct date: 2023-08-01, studyFirstPostDateStruct date: 2024-03-29, lastUpdatePostDateStruct date: 2024-04-01, sponsorCollaboratorsModule leadSponsor name: University of California, San Diego, class: OTHER, descriptionModule briefSummary: This study evaluates the impact of a fully digital, autonomous, and artificial intelligence (AI)-driven lifestyle coaching program on managing blood pressure (BP) among adults diagnosed with hypertension. Participants received a BP monitor and a wearable activity tracker to facilitate data collection. This data, along with responses from a questionnaire mobile app, were analyzed by an automated analytics engine employing statistical and machine learning techniques. The program delivered tailored lifestyle coaching directly to participants through a mobile app, aiming for precise and effective BP management., conditionsModule conditions: Hypertension, designModule studyType: INTERVENTIONAL, phases: NA, designInfo allocation: NA, interventionModel: SINGLE_GROUP, primaryPurpose: PREVENTION, maskingInfo masking: NONE, enrollmentInfo count: 141, type: ACTUAL, armsInterventionsModule interventions name: AI-Driven Lifestyle Coaching Program, outcomesModule primaryOutcomes measure: Average change in systolic blood pressure (SBP) from baseline to 12 weeks, primaryOutcomes measure: Average change in diastolic blood pressure (DBP) from baseline to 12 weeks, primaryOutcomes measure: Average change in SBP from baseline to 24 weeks, primaryOutcomes measure: Average change in DBP from baseline to 24 weeks, primaryOutcomes measure: Percent change of participants with controlled BP (SBP<130 and DBP<80) from baseline to 12 weeks, primaryOutcomes measure: Percent change of participants with controlled BP (SBP<130 and DBP<80) from baseline to 24 weeks, primaryOutcomes measure: Percent change of participants with Stage 2 Hypertension (SBP≥140 or DBP≥90) from baseline to 12 weeks, primaryOutcomes measure: Percent change of participants with Stage 2 Hypertension (SBP≥140 or DBP≥90) from baseline to 24 weeks, secondaryOutcomes measure: Average weekly percentage of active participants measuring their BP, secondaryOutcomes measure: Average weekly percentage of active participants syncing their wearable, secondaryOutcomes measure: Average weekly percentage of active participants answering the mobile app questionnaire, secondaryOutcomes measure: Number of manual clinician outreaches based on the escalation rules set for the study, eligibilityModule sex: ALL, minimumAge: 18 Years, stdAges: ADULT, stdAges: OLDER_ADULT, contactsLocationsModule locations facility: University of California, San Diego, city: La Jolla, state: California, zip: 92093, country: United States, geoPoint lat: 32.84727, lon: -117.2742, hasResults: False
protocolSection identificationModule nctId: NCT06337721, orgStudyIdInfo id: R01AA030786, type: NIH, link: https://reporter.nih.gov/quickSearch/R01AA030786, briefTitle: Preventing Alcohol Use Disorders and Alcohol-Related Harms in Pacific Islander Young Adults, statusModule overallStatus: NOT_YET_RECRUITING, startDateStruct date: 2024-09, primaryCompletionDateStruct date: 2028-05, completionDateStruct date: 2028-08, studyFirstPostDateStruct date: 2024-03-29, lastUpdatePostDateStruct date: 2024-03-29, sponsorCollaboratorsModule leadSponsor name: University of California, Riverside, class: OTHER, descriptionModule briefSummary: This study will: (1) refine and finalize the SPEAR intervention manual for preventing alcohol use disorders (AUD) and associated harms for Pacific Islander young adults; and (2) test SPEAR for efficacy by conducting a pretest-posttest randomized controlled trial (RCT)., conditionsModule conditions: Alcohol Use Disorder, conditions: Alcohol; Harmful Use, designModule studyType: INTERVENTIONAL, phases: NA, designInfo allocation: RANDOMIZED, interventionModel: PARALLEL, interventionModelDescription: Will conduct a randomized controlled trial of the SPEAR intervention vs. control group., primaryPurpose: PREVENTION, maskingInfo masking: NONE, enrollmentInfo count: 240, type: ESTIMATED, armsInterventionsModule interventions name: SPEAR (Strategies for Pacific Empowerment and Alcohol Reduction), outcomesModule primaryOutcomes measure: Heavy Episodic Drinking (HED) Days, secondaryOutcomes measure: Alcohol Consumption, eligibilityModule sex: ALL, minimumAge: 18 Years, maximumAge: 30 Years, stdAges: ADULT, contactsLocationsModule locations facility: UC Riverside, city: Riverside, state: California, zip: 91784, country: United States, geoPoint lat: 33.95335, lon: -117.39616, hasResults: False
protocolSection identificationModule nctId: NCT06337682, orgStudyIdInfo id: CB_CY_P09_23_11, briefTitle: Blood Pressure Management in the Care Home Population, acronym: BPITCH, statusModule overallStatus: ACTIVE_NOT_RECRUITING, startDateStruct date: 2016-01, primaryCompletionDateStruct date: 2020-01, completionDateStruct date: 2024-06, studyFirstPostDateStruct date: 2024-03-29, lastUpdatePostDateStruct date: 2024-03-29, sponsorCollaboratorsModule leadSponsor name: University of Leeds, class: OTHER, collaborators name: Bradford Teaching Hospitals NHS Foundation Trust, descriptionModule briefSummary: The UK care home population is projected to increase significantly over the coming decades. A high proportion of individuals in a care home have multiple long-term conditions and take large amounts of prescribed medication. This means they are routinely excluded from research studies and so there is little evidence on which to base treatment of long-term conditions such as high blood pressure. Furthermore, given that 1 in 4 people admitted into a care home die within 1 year, the benefit of treating high blood pressure to reduce the risk of heart attack or stroke must be balanced with the need to optimise quality of life. The aim of this study is to describe the health and social characteristics of the UK care home population with a particular focus on the management of blood pressure in the population. It is hoped that the findings of this study will help inform future research into the management of chronic conditions in care home residents., conditionsModule conditions: Aging, conditions: Hypertension, designModule studyType: OBSERVATIONAL, designInfo observationalModel: COHORT, timePerspective: RETROSPECTIVE, enrollmentInfo count: 3000, type: ESTIMATED, armsInterventionsModule, outcomesModule primaryOutcomes measure: Frequency of blood pressure measurements, primaryOutcomes measure: change in antihypertensive medication, primaryOutcomes measure: Injurious falls, secondaryOutcomes measure: Prevalence of hypertension, secondaryOutcomes measure: Antihypertensive medication, secondaryOutcomes measure: Blood pressure treatment, otherOutcomes measure: change in systolic pressure following care home admission, eligibilityModule sex: ALL, minimumAge: 65 Years, stdAges: OLDER_ADULT, contactsLocationsModule locations facility: Academic Unit for Ageing and Stroke Research, city: Bradford, state: West Yorkshire, zip: BD9 6RJ, country: United Kingdom, geoPoint lat: 53.79391, lon: -1.75206, hasResults: False
protocolSection identificationModule nctId: NCT06337656, orgStudyIdInfo id: VITAL_0, briefTitle: Vibration Training Approach in Liver Cirrhosis, acronym: VITAL, statusModule overallStatus: NOT_YET_RECRUITING, startDateStruct date: 2024-04-01, primaryCompletionDateStruct date: 2025-10-01, completionDateStruct date: 2026-04-01, studyFirstPostDateStruct date: 2024-03-29, lastUpdatePostDateStruct date: 2024-04-01, sponsorCollaboratorsModule leadSponsor name: University Hospital of Cologne, class: OTHER, descriptionModule briefSummary: * Comprehensive Investigation of the Impact of Side-Alternating Whole-Body Vibration Training on Muscle Mass and Muscle Strength in Patients with Liver Cirrhosis and Sarcopenia* Simultaneous Characterization and Evaluation of Dynamic Changes in Health-Related Quality of Life in our Patient Cohort with Liver Cirrhosis and Sarcopenia through Side-Alternating Whole-Body Vibration Training., conditionsModule conditions: Liver Cirrhosis, designModule studyType: INTERVENTIONAL, phases: NA, designInfo allocation: NON_RANDOMIZED, interventionModel: CROSSOVER, primaryPurpose: TREATMENT, maskingInfo masking: NONE, enrollmentInfo count: 20, type: ESTIMATED, armsInterventionsModule interventions name: Galileo WBV, outcomesModule primaryOutcomes measure: Evaluation of the Effectiveness on muscle strength, primaryOutcomes measure: Evaluation of the Effectiveness on muscle strength, primaryOutcomes measure: Evaluation of the Effectiveness on muscle strength, primaryOutcomes measure: Evaluation of the Effectiveness on muscle strength, primaryOutcomes measure: Evaluation of the Effectiveness on muscle mass, primaryOutcomes measure: Evaluation of the Effectiveness on muscle thickness, primaryOutcomes measure: Evaluation of the Effectiveness on mobility, in particular the risk of falling, primaryOutcomes measure: Evaluation of the Effectiveness on physical function, secondaryOutcomes measure: Evaluation of Safety of the Training Method, secondaryOutcomes measure: Health-Related Quality of Life, secondaryOutcomes measure: Health-Related Quality of Life, eligibilityModule sex: ALL, minimumAge: 18 Years, stdAges: ADULT, stdAges: OLDER_ADULT, hasResults: False
protocolSection identificationModule nctId: NCT06337643, orgStudyIdInfo id: MVX01-01, briefTitle: A Study to Evaluate Tolerability, Safety and Immunogenicity of MVX01 Pneumococcal Vaccine, statusModule overallStatus: ACTIVE_NOT_RECRUITING, startDateStruct date: 2023-03-07, primaryCompletionDateStruct date: 2024-04-16, completionDateStruct date: 2024-04-16, studyFirstPostDateStruct date: 2024-03-29, lastUpdatePostDateStruct date: 2024-03-29, sponsorCollaboratorsModule leadSponsor name: Matrivax Research and Development Corporation, class: INDUSTRY, descriptionModule briefSummary: The objectives of this first-in-human study is to evaluate the tolerability, safety, and immunogenicity of MVX01, a pneumococcal vaccine candidate, at four dose levels., conditionsModule conditions: Pneumococcal Vaccine, designModule studyType: INTERVENTIONAL, phases: PHASE1, designInfo allocation: RANDOMIZED, interventionModel: SEQUENTIAL, primaryPurpose: PREVENTION, maskingInfo masking: TRIPLE, maskingDescription: Cohort 1 is open-label. Cohorts 2-5 include two open-label sentinel participants each and the remainder of the participants are randomized and double-blind to either MVX01 or MVX01 Placebo (Participant \& Site)., whoMasked: PARTICIPANT, whoMasked: CARE_PROVIDER, whoMasked: INVESTIGATOR, enrollmentInfo count: 75, type: ESTIMATED, armsInterventionsModule interventions name: MVX01, interventions name: MVX01 Placebo, outcomesModule primaryOutcomes measure: Incidence of immediate reactogenicity adverse events, primaryOutcomes measure: Incidence of solicited reactogenicity events, primaryOutcomes measure: Incidence of adverse events (AEs), primaryOutcomes measure: Incidence of Serious Adverse Events (SAEs) and New-Onset Chronic Illness (NOCI), primaryOutcomes measure: Changes in safety laboratory results compared to baseline, primaryOutcomes measure: Changes in vital signs compared to baseline, primaryOutcomes measure: Geometric Mean Titer (GMT) post immunization of Anti-pneumolysin (PLY) and anti-choline binding protein A (CbpA), eligibilityModule sex: ALL, minimumAge: 18 Years, maximumAge: 75 Years, stdAges: ADULT, stdAges: OLDER_ADULT, contactsLocationsModule locations facility: Velocity (Meridian) Clinical Research, city: Savannah, state: Georgia, zip: 31406, country: United States, geoPoint lat: 32.08354, lon: -81.09983, locations facility: Alliance for Multispecialty Research (AMR), city: Knoxville, state: Tennessee, zip: 37909, country: United States, geoPoint lat: 35.96064, lon: -83.92074, hasResults: False
protocolSection identificationModule nctId: NCT06337604, orgStudyIdInfo id: TNP-2092-04, briefTitle: The Safety and Tolerability, Pharmacokinetics of TNP-2092 Capsules in Combination With Rabeprazole Sodium Enteric-coated Tablets, statusModule overallStatus: COMPLETED, startDateStruct date: 2017-10-10, primaryCompletionDateStruct date: 2017-11-23, completionDateStruct date: 2017-11-23, studyFirstPostDateStruct date: 2024-03-29, lastUpdatePostDateStruct date: 2024-04-01, sponsorCollaboratorsModule leadSponsor name: TenNor Therapeutics Inc., class: INDUSTRY, descriptionModule briefSummary: A phase 1, single-center, double-blind, randomized, placebo-controlled clinical trial to evaluate the safety and tolerability, pharmacokinetics, and preliminary efficacy of multiple administrations of TNP-2092 Capsules in combination with Rabeprazole Sodium Enteric-coated Tablets in asymptomatic healthy subjects with Helicobacter pylori infection, conditionsModule conditions: Helicobacter Pylori Infection, designModule studyType: INTERVENTIONAL, phases: PHASE1, designInfo allocation: RANDOMIZED, interventionModel: PARALLEL, primaryPurpose: TREATMENT, maskingInfo masking: DOUBLE, whoMasked: PARTICIPANT, whoMasked: INVESTIGATOR, enrollmentInfo count: 20, type: ACTUAL, armsInterventionsModule interventions name: TNP-2092 capsules, interventions name: TNP-2092 capsules placebo, interventions name: Rabeprazole sodium enteric-coated tablets, outcomesModule primaryOutcomes measure: Area Under the Plasma Concentration Versus Time Curve Extrapolated to Infinity (AUC0-inf), primaryOutcomes measure: Area Under the Plasma Concentration Versus Time Curve from 0 to the Last Measurable Concentration (AUC0-t), primaryOutcomes measure: Maximum Observed Plasma Concentration (Cmax) of TNP-2092, primaryOutcomes measure: Percentage of Participants With Adverse Events (AEs), eligibilityModule sex: ALL, minimumAge: 18 Years, maximumAge: 50 Years, stdAges: ADULT, contactsLocationsModule locations facility: The First Hospital of Jilin University, city: Changchun, state: Jilin, country: China, geoPoint lat: 43.88, lon: 125.32278, hasResults: False